Company Description

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics.

It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.

The company was founded in 2020 and is based in San Diego, California.

Revelation Biosciences, Inc.

Country	United States
Founded	2020
Industry	Biotechnology
Sector	Healthcare
Employees	9
CEO	James Rolke

Contact Details

Address: 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 United States
Phone	650 800 3717
Website	revbiosciences.com

Stock Details

Ticker Symbol	REVB
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001810560
CUSIP Number	76135L101
ISIN Number	US76135L5075
Employer ID	84-3898466
SIC Code	2834

Key Executives

Name	Position
James M. Rolke	Chief Executive Officer and Director
Chester Stanley Zygmont III	Chief Financial Officer and Corporate Secretary
Sandra Vedrick	Vice President of Human Resources and Investor Relations
Carol Odle	Senior Director of Clinical Projects

Latest SEC Filings

Date	Type	Title
Nov 8, 2024	8-K	Current Report
Nov 8, 2024	10-Q	Quarterly Report
Oct 21, 2024	8-K	Current Report
Sep 27, 2024	8-K	Current Report
Sep 25, 2024	UPLOAD	Filing
Sep 23, 2024	10-Q/A	[Amend] Quarterly report
Sep 23, 2024	10-Q/A	[Amend] Quarterly report
Sep 23, 2024	10-K/A	[Amend] Annual report
Sep 13, 2024	424B3	Prospectus
Sep 13, 2024	UPLOAD	Filing

View All SEC Filings